Literature DB >> 20139942

Fab-arm exchange.

Ellen Broug, Philip A Bland-Ward, John Powell, Kevin S Johnson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20139942     DOI： 10.1038/nbt0210-123

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  15 in total

1.  Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.

Authors:  B K Kleinschmidt-DeMasters; Kenneth L Tyler
Journal:  N Engl J Med       Date:  2005-06-09       Impact factor: 91.245

2.  Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.

Authors:  Ganesh Suntharalingam; Meghan R Perry; Stephen Ward; Stephen J Brett; Andrew Castello-Cortes; Michael D Brunner; Nicki Panoskaltsis
Journal:  N Engl J Med       Date:  2006-08-14       Impact factor: 91.245

3.  Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange.

Authors:  Marijn van der Neut Kolfschoten; Janine Schuurman; Mario Losen; Wim K Bleeker; Pilar Martínez-Martínez; Ellen Vermeulen; Tamara H den Bleker; Luus Wiegman; Tom Vink; Lucien A Aarden; Marc H De Baets; Jan G J van de Winkel; Rob C Aalberse; Paul W H I Parren
Journal:  Science       Date:  2007-09-14       Impact factor: 47.728

4.  Immunology. Square-dancing antibodies.

Authors:  Dennis R Burton; Ian A Wilson
Journal:  Science       Date:  2007-09-14       Impact factor: 47.728

5.  Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA.

Authors:  E Iacobaeus; C Ryschkewitsch; M Gravell; M Khademi; E Wallstrom; T Olsson; L Brundin; Eo Major
Journal:  Mult Scler       Date:  2008-09-19       Impact factor: 6.312

6.  Normal human immunoglobulin G4 is bispecific: it has two different antigen-combining sites.

Authors:  J Schuurman; R Van Ree; G J Perdok; H R Van Doorn; K Y Tan; R C Aalberse
Journal:  Immunology       Date:  1999-08       Impact factor: 7.397

Review 7.  IgG4 breaking the rules.

Authors:  Rob C Aalberse; Janine Schuurman
Journal:  Immunology       Date:  2002-01       Impact factor: 7.397

8.  Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo.

Authors:  Aran F Labrijn; Antonio Ortiz Buijsse; Ewald T J van den Bremer; Annemiek Y W Verwilligen; Wim K Bleeker; Susan J Thorpe; Joep Killestein; Chris H Polman; Rob C Aalberse; Janine Schuurman; Jan G J van de Winkel; Paul W H I Parren
Journal:  Nat Biotechnol       Date:  2009-07-20       Impact factor: 54.908

9.  Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.

Authors:  Kenneth R Carson; Andrew M Evens; Elizabeth A Richey; Thomas M Habermann; Daniele Focosi; John F Seymour; Jacob Laubach; Susie D Bawn; Leo I Gordon; Jane N Winter; Richard R Furman; Julie M Vose; Andrew D Zelenetz; Ronac Mamtani; Dennis W Raisch; Gary W Dorshimer; Steven T Rosen; Kenji Muro; Numa R Gottardi-Littell; Robert L Talley; Oliver Sartor; David Green; Eugene O Major; Charles L Bennett
Journal:  Blood       Date:  2009-03-05       Impact factor: 22.113

Review 10.  alpha4-Integrin antagonism with natalizumab: effects and adverse effects.

Authors:  Olaf Stüve; Ralf Gold; Andrew Chan; Eilhard Mix; Uwe Zettl; Bernd C Kieseier
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849
View more
  4 in total

1.  An Evaluation of 20 Years of EU Framework Programme-Funded Immune-Mediated Inflammatory Translational Research in Non-Human Primates.

Authors:  Krista G Haanstra; Margreet Jonker; Bert A 't Hart
Journal:  Front Immunol       Date:  2016-11-07       Impact factor: 7.561

2.  Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate.

Authors:  Peter Herbener; Kurt Schönfeld; Martin König; Matthias Germer; Jude M Przyborski; Katrin Bernöster; Jörg Schüttrumpf
Journal:  PLoS One       Date:  2018-04-19       Impact factor: 3.240

3.  Coming together at the hinges: Therapeutic prospects of IgG3.

Authors:  Thach H Chu; Edward F Patz; Margaret E Ackerman
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

4.  Evaluation of Antibody Properties and Clinically Relevant Immunogenicity, Anaphylaxis, and Hypersensitivity Reactions in Two Phase III Trials of Tralokinumab in Severe, Uncontrolled Asthma.

Authors:  Mats Carlsson; Martin Braddock; Yuling Li; Jihong Wang; Weichen Xu; Nicholas White; Ayman Megally; Gillian Hunter; Gene Colice
Journal:  Drug Saf       Date:  2019-06       Impact factor: 5.606
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.